Urogen Pharma

URGN NASDAQ
32.01
+0.78
+2.50%
After Hours: 32.01 0 0.00% 16:00 08/16 EDT
Open
31.36
Prev Close
31.23
High
32.19
Low
31.14
Volume
62.06K
Avg Vol (3M)
186.61K
52 Week High
55.49
52 Week Low
30.48
% Turnover
0.30%
Market Cap
668.94M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Urogen Pharma URGN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.
MORE >

Recently

Name
Price
%Change